These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Unmasking and successful management of light chain deposition disease of kidney in pregnancy: a complex case, mirroring the complex needs of pregnancy with kidney disease in India. Matthai SM; Jacob S; Devasia AJ; Bindra M; David VG; Varughese S J Nephrol; 2018 Oct; 31(5):785-791. PubMed ID: 30187379 [TBL] [Abstract][Full Text] [Related]
28. Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab? Kuypers DR; Lerut E; Claes K; Evenepoel P; Vanrenterghem Y Transpl Int; 2007 Apr; 20(4):381-5. PubMed ID: 17326779 [TBL] [Abstract][Full Text] [Related]
29. Cerebral low-grade lymphoma and light chain deposition disease: exceedingly high IgG levels in the cerebrospinal fluid as a diagnostic clue. Pantazis G; Psaras T; Krope K; von Coelln R; Fend F; Bock T; Schittenhelm J; Melms A; Meyermann R; Bornemann A Clin Neuropathol; 2010; 29(6):378-83. PubMed ID: 21073842 [TBL] [Abstract][Full Text] [Related]
30. Clinical challenges of an oligosecretory plasma cell dyscrasia. Rodrigues L; Neves M; Sá H; Campos M BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23420725 [TBL] [Abstract][Full Text] [Related]
31. [Light chain deposition disease. Experience in our environment]. Martín Herrera C; Suñer Poblet M; Cabrera R; Díaz Pedrero M; Fernández Alonso J Nefrologia; 2008; 28(5):539-42. PubMed ID: 18816213 [TBL] [Abstract][Full Text] [Related]
33. A descriptive study of plasma cell dyscrasias in Egyptian population. Kassem NM; El Zawam H; Kassem HA; El Nahas T; El Husseiny NM; El Azeeim HA J Egypt Natl Canc Inst; 2014 Jun; 26(2):67-71. PubMed ID: 24841156 [TBL] [Abstract][Full Text] [Related]
34. [The concurrence of light-chain deposition disease, AL-amyloidosis, and cast nephropathy in a patient with multiple myeloma]. Rekhtina IG; Zakharova EV; Stolyarevich ES; Sinitsina MN; Denisova EN Ter Arkh; 2015; 87(6):98-101. PubMed ID: 26281203 [TBL] [Abstract][Full Text] [Related]
35. Cutaneous Light Chain Deposition Disease: A Report of 2 Cases and Review of the Literature. Hendricks C; Fernández Figueras MT; Liersch J; Martin-Urdà MT; López D; Brochhausen C; Röcken C; Schaller J Am J Dermatopathol; 2018 May; 40(5):337-341. PubMed ID: 28953013 [TBL] [Abstract][Full Text] [Related]
36. Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease. Kimura S; Ohkawara H; Ogawa K; Tanaka M; Sano T; Harada-Shirado K; Takahashi H; Ueda K; Shichishima-Nakamura A; Matsumoto H; Ikeda K; Kazama JJ; Hashimoto Y; Ikezoe T Intern Med; 2018 Dec; 57(24):3651-3657. PubMed ID: 30101913 [TBL] [Abstract][Full Text] [Related]
37. Light chain deposition disease developing 15 years following the diagnosis of monoclonal gammopathy of undetermined significance. Okura T; Miyoshi K; Nagao T; Jotoku M; Enomoto D; Irita J; Kurata M; Higaki J Intern Med; 2009; 48(2):101-4. PubMed ID: 19145054 [TBL] [Abstract][Full Text] [Related]